On this page
When are accelerated-approval promotional materials submitted to FDA?
Unless FDA informs the applicant otherwise, the regulations described in guidance IV.B require preapproval submission of materials intended for use within 120 days after marketing approval, and submission at least 30 days before initial use for the subsequent period. Verify the actual product conditions and dates. Prepare matching drafts and support, and keep presubmission, agency comments and final 2253 reporting as separate events.
Before you begin
Promotional presubmissions for products subject to accelerated-approval promotional conditions. Confirm the current product-specific conditions and agency instructions; this task differs from voluntary advisory review and subsequent 2253 reporting.
What you will prepare: A traceable presubmission package with an evidence-based timing assessment and clean/annotated materials.
Read the product conditions before setting a date
Section IV.B describes accelerated-approval presubmission, including launch material intended for the first 120 days after marketing approval and the subsequent non-launch framework, unless FDA informs the applicant otherwise. Retrieve the actual approval/conditions and planned dissemination date. Have the regulatory owner verify the governing timing, including any specific agency direction, rather than deriving a release date solely from this guide or a catalog heading.
Show the entire intended presentation
Identify the presubmission purpose, application, launch state, audience, material IDs and prior interactions. Prepare matching clean and annotated material, applicable current labeling and pinpoint references. Keep unsupported claims and unresolved wording visible in the review issues list. Form handling differs between OPDP and APLB draft submissions; use the appropriate office’s instructions instead of reusing a standard final-material package.
Separate review, response and dissemination decisions
Track the submission, agency comments, revisions and intended release independently. Record who evaluated whether a revised claim changes the package or timing decision. Submission acceptance is a technical event; it does not prove a promotional claim is acceptable. Reconcile the final disseminated version with the reviewed draft and the applicable reporting workflow.
Fictional example: a launch date moves
A campaign originally planned within the launch period is moved later. Reassess whether the applicable category and timing instructions change; do not retain the original classification merely because files are already prepared. If the approval conditions cannot be located, gather materials and annotations but leave release authorization unresolved until the responsible owner establishes the actual conditions.
Document the timing basis before committing the campaign
Use the actual approval and agency correspondence to build a timing record. A general regulatory rule cannot establish whether FDA gave different instructions for this product or whether the campaign date has moved.
| Decision | Evidence to record | Consequence |
|---|---|---|
| Applicable conditions | Approval pathway, product-specific terms and subsequent FDA direction | Establish whether and how presubmission applies |
| Launch versus later use | Marketing approval date and intended first dissemination/publication | Determine the relevant timing framework |
| Intended package | Each material ID, audience, medium, version and use date | Include the actual pieces affected by the plan |
| Submission event | Actual submitted content, receipt record and date | Distinguish completed submission from an internal target |
| Revision | Changed claims or presentation and prior-comment disposition | Reassess the appropriate package and timing with the responsible owner |
| Release and reporting | Actual final version, decision record and first use | Reconcile final reporting separately from draft presubmission |
Under 21 CFR 314.550 and 601.45, the launch framework concerns materials intended for dissemination or publication within 120 days following marketing approval; the later framework specifies at least 30 days before intended initial use, unless otherwise informed by FDA. Do not turn the 120-day period into permission to submit launch materials after approval simply because the campaign has not started. Conversely, do not describe the later 30-day provision as a guarantee that FDA will comment by that date or as automatic promotional approval.
Fictional planning exercise: a material is explicitly planned for day 150 after approval, and the proposed submission-to-use interval is 20 days. Under the ordinary later-use rule, that interval does not satisfy the stated minimum. The team must resolve the actual product conditions and schedule before release. This arithmetic illustrates the rule; it does not authorize a particular campaign date or assume that any revised material retains an earlier submission date.
If the firm intends to disseminate submitted accelerated-approval material without waiting for comments, guidance IV.E describes a general-correspondence notification in the applicable circumstances. If it decides not to use the material, IV.G describes withdrawal. Do not use withdrawal to make a required presubmission disappear while still planning to disseminate the same material.
The draft package includes clean and annotated materials, applicable current labeling and relevant support. Form handling differs by office; the guidance describes APLB draft Form FDA 2253 use and says not to use that form for these OPDP draft submissions. Use the material-evidence guide, then reconcile the eventual current-label artifact for final reporting.
Your preparation checklist
0/3 checkedUse this to track your review in this visit. Checks are not saved and do not establish regulatory compliance.
Frequently asked questions
Are the accelerated-approval launch materials submitted only after approval?
Unless FDA informs the applicant otherwise, 314.550 and 601.45 specify submission during preapproval review of promotional materials intended for use within 120 days after marketing approval. Establish the actual product conditions. The 120-day window describes intended use, not a general postapproval submission grace period.
Does the 30-day presubmission interval guarantee FDA approval or comments?
No. The later-use provision specifies submission timing, subject to the actual agency instructions; it does not promise comments within that interval or confer approval on the material. Keep receipt, comments, revisions and the company’s release decision separately documented, with final reporting assessed on its own basis.
Can required promotional presubmission be withdrawn while the same material is still planned for use?
Guidance IV.G says withdrawal for accelerated-approval materials should be used only if the firm does not plan to disseminate or publish them. IV.E describes notification when the firm plans use without waiting for comments in the applicable circumstances. Verify the product conditions rather than using withdrawal as a timing workaround.
Does the draft presubmission replace final Form FDA 2253 reporting?
No. The presubmission and final postmarketing report are separate events with different material states and preparation instructions. Reconcile the version actually disseminated with the reviewed draft, current labeling and applicable final reporting. A previously submitted draft is not proof that the final material was reported.
Sources and revisions
Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.
Guidance
FDA: Submissions of Promotional Labeling and Advertising ↗April 2022 final, Revision 1; IV.A–J, VI.E–H and VII. PDF production/PRA update April 2023 does not change the cover revision. Its legacy backbone syntax is not an eCTD v4 implementation guide. Checked September 22, 2026.
Technical specification · placement only
FDA eCTD v4.0 comprehensive hierarchy ↗Version 2.2, February 2025. Section 1.15.1.3. A heading identifies placement, not mandatory applicability.